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Abstract
Selenium and sulfur are two closely related basic elements utilized in nature for a vast array of biochemical reactions. While
toxic at higher concentrations, selenium is an essential trace element incorporated into selenoproteins as selenocysteine
(Sec), the selenium analogue of cysteine (Cys). Sec lyases (SCLs) and Cys desulfurases (CDs) catalyze the removal of selenium
or sulfur from Sec or Cys and generally act on both substrates. In contrast, human SCL (hSCL) is specific for Sec although the
only difference between Sec and Cys is the identity of a single atom. The chemical basis of this selenium-over-sulfur
discrimination is not understood. Here we describe the X-ray crystal structure of hSCL and identify Asp146 as the key residue
that provides the Sec specificity. A D146K variant resulted in loss of Sec specificity and appearance of CD activity. A dynamic
active site segment also provides the structural prerequisites for direct product delivery of selenide produced by Sec
cleavage, thus avoiding release of reactive selenide species into the cell. We thus here define a molecular determinant for
enzymatic specificity discrimination between a single selenium versus sulfur atom, elements with very similar chemical
properties. Our findings thus provide molecular insights into a key level of control in human selenium and selenoprotein
turnover and metabolism.
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Introduction
As an essential trace element, selenium is incorporated into
selenoproteins in the form of selenocysteine (Sec), the selenium
analogue of cysteine (Cys), by a co-translational process redefining
specific UGA codons thereby expanding the genetic code [1,2].
The human genome contains 25 known genes encoding
selenoproteins some of which are essential for mammals [3]. In
spite of its important role as the defining entity of selenoproteins,
selenium can also be severely toxic because of high chemical
reactivity of metabolites such as selenite and hydrogen selenide
[4,5,6]. Thus it becomes crucial for selenoprotein-dependent
organisms to have adequate selenium intake as well as to develop
means for tight control of the selenium metabolism. One unique
property in synthesis of Sec, likely developed as a means of
controlling its reactivity, is the fact that Sec, in contrast to the 20
other common amino acids, is not loaded as such onto its cognate
tRNA but is instead synthesized directly on tRNA
Sec. This tRNA
species is initially amino acylated with a seryl residue, tRNA
Sec[-
Ser], which in archaea and eukaryotes is converted to tRNA
Sec[Sec]
via an O-phosphoseryl-tRNA
Sec[Ser] intermediate by Sec synthase,
utilizing selenophosphate as the selenium donor [7,8,9]. Recently
the structural basis for this step was revealed through studies of a
crystal structure of the human SepSecS-tRNA
Sec complex [10].
Selenophosphate is provided by at least one isoform of selenopho-
sphate synthetase (SPS), utilizing selenide and ATP [8]. The
source of selenide for that reaction may derive from either selenite
reduction, in a reaction that may be catalyzed by thioredoxin
reductase [11], from conversion of methylated low molecular
weight selenium compounds [12], or through selenium removal
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5from Sec as catalyzed by Sec lyase (SCL) [13,14,15,16]. Sec as a
precursor for the latter reaction should derive from all events of
selenoprotein degradation. This path may be of particular
importance for the high selenium retention in brain or in other
tissues where selenoprotein synthesis is dependent upon selenium
derived from degradation of selenoprotein P [5,17]. If free Sec
would be released from selenoprotein degradation it should easily
be detrimental to a cell due to its inherent chemical reactivity and
Sec catabolism must therefore be tightly controlled. The Sec
degradation step, as catalyzed by SCL, can thus be expected to be
regulated and of high capacity. Interestingly, human SCL (hSCL)
is unlike several bacterial orthologues specific for Sec and does not
accept the sulfur analogue Cys as substrate with any appreciable
activity. Instead of displaying Cys desulfurase (CD) activity, hSCL
is even inhibited by addition of excess Cys [13,18,19,20].
Sequence similarity analyses and available biochemical data
[13,16] suggest that the presence of a SCL specific for Sec is a
feature of higher eukaryotes, well in line with the need for a strict
control of selenium metabolism in these selenoprotein-dependent
organisms. SCL from pig was the first enzyme discovered to act
specifically on selenium compounds [13].
SCL and CD enzymes are NifS-like proteins that contain a
completely conserved active site Cys residue (C388, hSCL
numbering) that form an enzyme-bound persulfide (Cys-S-SH)
or sulfoselenide (Cys-S-Se
2) as product of the reactions with Cys
or Sec, respectively [21]. The (Cys-S-Se
2) species is commonly
also denoted ‘‘perselenide’’ in the literature but here sulfoselenide
is used to avoid confusion with a Sec-Se-Se
2 perselenide. NifS
proteins can be divided into two major groups (groups I and II)
based on sequence characteristics [22], but enzymes of lower
organisms from either group were shown to have both SCL and
CD activity [20,22]. Group-I proteins, to which the SCLs of
higher eukaryotes belong, contain a 10- to 12-residue insertion
compared to group II. This produces a larger segment
encompassing the active site Cys that is conserved in all enzymes
from both groups. In structures of group-I enzymes, this segment is
commonly disordered and not visible in the electron density.
During recent years it has become clear that persulfides serve as
the predominant sulfur donors in synthesis of sulfur-containing
biomolecules and that enzymes involved in metabolism of sulfur
compounds often form protein-protein complexes to traffic or
deliver the sulfur atom [23,24,25]. Because of the relative rarity of
selenium compared to sulfur, its higher chemical reactivity and its
toxicity, defined and controlled trafficking events for selenium are
expected to be even more important than for sulfur. This imposes
a challenging task on organisms, considering the close similarities
between sulfur and selenium in terms of chemical properties.
Though less studied than their counterparts involved in sulfur
metabolism, a body of data is emerging indicating that eukaryotic
SCL proteins, as well as their bacterial orthologues, may be
involved not only in selenium assimilation and Sec recycling, but
also in controlled delivery of selenium for selenophosphate
synthesis [16,19,26,27,28,29,30,31].
The structural and chemical basis for the important and strict
selenium specificity of eukaryotic SCLs remains unclear. A recent
study of a SCL from rat (rSCL) crystal structure reports slightly
different binding modes for Cys and selenopropionate, used as a
Sec substrate analogue, suggesting this to be the basis for specificity
[32]. In the same study, Cys was found to reversibly form a
nonproductive adduct with rSCL while selenopropionate bound in
two different conformations [32]. The specific production of a
sulfoselenide adduct to the active site Cys residue was also shown
[32]. However, the guiding mechanism for the substrates, and
whether the lack of an amine on the Sec substrate analogue that
was used influenced its binding remains an open question. Here,
we present the crystal structure of hSCL, which helps resolve this
question. Using a structure-guided bioinformatic approach, a
single Asp residue that confers Sec specificity was identified and we
could subsequently design variant proteins that gained CD activity
in addition to having maintained SCL activity, thus defining a
molecular determinant for Sec specificity of the wild-type enzyme.
The structure also revealed the features of the dynamic active site
segment including the conserved C388, suggested to allow control
and delivery of the selenide produced in the Sec lyase reaction.
Results
Overall structure
Structures of hSCL in two different crystal forms were
determined: P1 to 1.8 A ˚, with four monomers per asymmetric
unit and P212121 to 2.1 A ˚ resolution, with two monomers per
asymmetric unit (Table 1). Similar to the non-specific SCL/CD
enzymes, hSCL was found to adopt the canonical fold type I
structure of PLP enzymes [33], forming two active sites in the
homodimer interface with each monomer contributing residues to
both active sites (Fig. 1A).
Table 1. Data collection and refinement statistics.
Structure 1 Structure 2
Data collection*
Space group P212121 P1
Cell dimensions
a, b, c (A ˚) 59.2, 85.8, 188.6 66.6, 72.2, 89.4
a, b, g (u) 90, 90, 90 83.9, 68.4, 87.0
Resolution (A ˚) 20.0-2.10 (2.20-2.10) 30.0-1.80 (1.90-1.80)
Rsym 9.9 (34.4) 5.1 (52.7)
I/sI 13.1 (5.7) 16.2 (2.2)
Completeness (%) 99.8 (100.0) 94.1 (93.5)
Redundancy 7.1 (7.3) 2.0 (2.0)
Wilson B-factor 36.0 22.5
Refinement
Resolution (A ˚) 20.0-2.10 30.0-1.80
No. reflections 56897 134466
Rwork/Rfree 0.182/0.235 0.184/0.217
No. atoms
Protein 6197 12210
Ligand/ion 30 76
Water 457 899
B-factors
Protein 33.2 15.3
Ligand/ion 27.5 23.6
Water 36.0 27.8
R.m.s. deviations
Bond lengths (A ˚) 0.018 0.014
Bond angles (u) 1.70 1.46
PDB accession code 3GZC 3GZD
One crystal was used for each structure.
*Values in parentheses are for highest-resolution shell.
doi:10.1371/journal.pone.0030581.t001
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active site cysteine
In the P212121 structure, the segment containing C388 (residues
385–396) was ordered in both subunits of the asymmetric unit.
Interestingly, it adopted two different ordered conformations in
the two monomers. In subunit A, the segment was folded onto the
protein in a near a-helical ‘‘closed’’ conformation, restricting
access to the active site and placing the active site C388 in
proximity to the PLP cofactor. In contrast, the corresponding
active site segment of subunit B displayed an extended b-hairpin
structure (Fig. 1B), positioning C388 more than 17 A ˚ from the
PLP cofactor and exposing it to solvent. An electron density omit
map for the segment surrounding C388 in monomers A and B is
shown in stereo figures 2A and B respectively.
The peptide backbone of the dynamic segment containing the
conserved active site Cys did not align in space with its counterpart
found in available structures of group-II NifS-like proteins.
Remarkably, in spite of the completely different backbone
architecture, the closed conformation of hSCL positioned the
C388 sulfur atom in an identical position in relation to the PLP
cofactor and substrate-binding site as observed in the group-II
proteins. In the E. coli group-II NifS protein, both persulfide and
sulfoselenide intermediates have been shown to be produced at the
active site cysteine with this particular reaction geometry [21]
(Fig. 3A). Moreover, in a second crystal form (P1) of hSCL,
crystallized at a higher pH of 8.1 and soaked with 10 mM Cys for
2 hours, the electron density of subunit A showed the formation of
an adduct, most likely a C388-persulfide, to C388 in the closed
conformation (Fig. 3B). The persulfide adduct was present in
subunit A with near full occupancy and also in subunit D, but
there at lower occupancy. Together, this strongly suggests that the
closed conformation observed in the present structure is involved
in catalysis and C388-sulfoselenide formation using Sec as a
substrate. The formation of a C388-persulfide after 2 hr
incubation with 10 mM Cys is also an important clue to the
chemical basis for the inherent Sec specificity of the enzyme
because it indicates that hSCL is not, at least under these
crystallization conditions, absolutely specific for Sec but may
perform Cys desulfurization with extensive concentrations of Cys
over very long time scales. However, this should have no biological
Figure 1. Structure of Human SCL. A) Human SCL homodimer in complex with the co-factor PLP. The C388 residues of both subunits are
indicated. B) Superposed subunits A and B of human SCL showing the structural differences in the active site segment and positioning of C388
(subunit A: pink ‘‘closed’’ and subunit B: cyan ‘‘open’’), the location of Asp 146 is also shown.
doi:10.1371/journal.pone.0030581.g001
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[13,16,18]. It should be noted that although the dynamic segment
(residues 385–396) was visible in the electron density in both
subunits in the P212121 structure it seemed less rigid than the rest
of the protein, as indicated by higher B-factors and a somewhat
weaker electron density. In particular the density for Gly 393 of
subunit B was poor. The inherent dynamic property of this
segment was also confirmed by the structure in the P1 crystal form
where, similar to structures of other Group-I enzymes, it was
disordered to different degrees in all four monomers of the
asymmetric unit. Residues A 391–394, B 386–394, C 389–393
and D 391–394 are missing from the electron density in this
crystal. It appears that the dynamics of this particular protein
segment is a common feature among group-I NifS-like proteins.
Gain-of-function substitutions
To be able to study the chemical basis for Sec specificity, we
endeavored to produce gain-of-function variant proteins with
acquired CD activity. Based on the hSCL structure and sequence
alignments between non-specific and Sec-specific enzymes, we
identified three residues in the active site vicinity that could be
thought to contribute to the Sec specificity (Fig. 3C and Fig. 4).
Two of the residues (D146 and H389) are positioned less than 4 A ˚
from C388, essentially in direct van der Waals contact. Residues
corresponding to D146 are conserved as Asp in higher eukaryotes
but are found as Lys in other Group-I proteins or as His in Group-
II proteins (Fig. 4, yellow). Residues corresponding to H389 are
conserved as His in higher eukaryotes, but found as Thr or Ala in
non-specific proteins (Fig. 4, purple). The third selected residue
(V256) is in van der Waals contact with the PLP cofactor. This
residue is conserved as Val in higher eukaryotes but replaced by
Ser (or in a few cases Thr) in other organisms (Fig. 4, green). Based
on these evolutionary clues we generated D146K, H389T and
V256S variants and we expressed, purified and analyzed the seven
possible combinations of these hSCL substitutions. Activity assays
revealed that a novel CD activity was obtained for all of the
variants containing the D146K substitution (Fig. 5A). In the
absence of the D146K substitution the other substitutions did not
confer detectable activity with Cys. The activity with Sec observed
in the wild-type enzyme was not altered within experimental error
in the D146K/H389T variant (Fig. 5B) and the initial rate was
several-fold higher than with Cys for the variant enzymes (Fig. 5A).
As both substrates were initially present at an equivalent of
10 mM, the reduction in activity (curvature) in the reaction with
Sec after <10 minutes is likely due to some form of product
inhibition or depletion of the Sec substrate by a competing non-
enzymatic reaction.
Discussion
Gain-of-function for cysteine desulfurase activity
By using a structure-guided bioinformatic approach we were
here able to identify a number of residues that potentially could
influence the substrate specificity of SCL enzymes. Among these
variants, change of the single Asp146 residue to Lys proved
necessary and sufficient to achieve CD functionality in hSCL.
Double and triple mutants, including the D146K variation, all
showed CD activity. The other variations, H389T and V256S,
influenced the activity only slightly when combined with the
D146K variation but did not yield any detectable CD activity in
the absence of the D146K variation. These results are consistent
with available specificity data for SCL/CD enzymes and should
allow for more robust bioinformatic assignments of Sec/Cys
specificity in SCL/CD enzymes. The residue that, upon charge
inversion, confers gain-of-function for CD activity is located close
to C388, but distant from both the PLP cofactor and the substrate-
binding site. This could suggest that the chemical properties of
C388 are directly involved in the observed specificity of hSCL. A
study of the mechanistic implications of the D146K change is
described in an accompanying paper [34].
Previous studies of hSCL have reported Km of 0.5 mM with Sec
and a Ki for Cys of 5.85 mM [18]. The kcat for mouse SCL with
Sec has been reported as 46 s
21 with a Km of 9.9 mM and in that
study catalytic parameters for Cys as the substrate was also
reported with a kcat of 0.0058 s
21 and a Km of 5.2 mM [16].
These numbers for Km may appear high considering the expected
low concentration of Sec substrate in the cell, possibly suggesting
the importance of protein-protein interactions during delivery of
substrates to SCL. Still, Km is a kinetic parameter and not directly
related to the dissociation constant Kd. The high Ki value for Cys
would also indicate that hSCL is not significantly inhibited by free
Cys at any physiological concentrations. Future studies of hSCL
activities in a cellular context are needed to further address these
questions and the role(s) of hSCL in vivo. In the present study we
have reached novel insights into the structural determinants for its
activity and enzymatic properties.
Possibilities for product protection and delivery
The reaction of SCL/CD enzymes with Sec results in a
selenium-charged enzyme in the form of an enzyme-bound Cys-
sulfoselenide [20,21,22,32]. Interestingly, in group-I enzymes, this
cysteine (C388 hSCL numbering) appears universally located in a
dynamic segment, shown to be able to adopt at least two ordered
states in hSCL (this work). In addition, a disordered state was
observed in the P1 crystal of hSCL, as previously described also for
other group I enzymes.
The hSCL structure shows that in the closed state, relevant for
sulfoselenide formation, the reactive sulfur atom of C388 is buried
in the protein and completely covered by the residues of the
dynamic segment (Fig. 6A). However, in the open form, the sulfur
atom is exposed and accessible to solvent (Fig 6B). It thus appers
possible that the closed conformation can function not only in
catalysis to support the sulfoselenide formation, but also as a
storage conformation preventing the sulfoselenide to react
unspecifically with surrounding cellular components. Possibly,
interaction of SCL with selenophosphate synthetase (SPS), the
enzyme in the Sec synthesis pathway using selenide as substrate,
may trigger opening of the dynamic segment in SCL allowing
direct delivery of selenide for SPS catlysis (Fig. 6B and Fig. 7).
Several studies have indeed shown that NifS-like proteins can
mobilize selenium from Sec in order for the selenide to act as a
substrate for selenophosphate synthesis by SPS [19,26,27,30]. SPS
proteins contain a residue, close to the N-terminus, that is
conserved as either Cys or Sec. That residue, C17 in E. coli SPS,
has been suggested as a site accepting selenide in the wild-type
protein, based upon isotope labeling experiments [35] and also
supported by a recent structure of the Aquiflex aeolicus SPS [36].
Interestingly, only one of the two SPS homologs present in human,
hSPS2, contain the corresponding Sec residue while hSPS1
contain a threonine in the corresponding position. Biochemical
studies suggest that hSPS2 is used for selenite assimilation while
hSPS1 is used for recycling of Sec, likely via the action of SCL
[30]. An interesting observation in this context is that the E. coli
SPS protein C17S variant is completely inactive in the standard in
vitro assay with selenide as a substrate. In contrast, if selenium is
provided as Sec together with any of the three E. coli NifS
homologs (that all have SCL activity) the activity is partly restored
[27]. In light of these results it is possible to suggest that the Sec/
Selenium Specificity of Human Selenocysteine Lyase
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selenide substrate and deliver it to the active site. However, if the
selenium would be provided in the form of a Cys sulfoselenide in
the flexible active site segment of SCL, it could be delivered
directly to the SPS active site via a SCL-SPS protein-protein
interaction. The SCL Cys sulfoselenide would then replace
delivery by the intramolecular Sec/Cys containing flexible loop
in SPS (Fig. 7). In this context it is interesting to note that a recent
study showed coimmunoprecipitation of the SCL and both SPS
proteins from mouse [37]. However, other studies suggest that
SPS1 does not play a direct role in selenocysteine metabolism
[38,39]. Further studies are clearly needed to firmly establish these
complicated pathways.
Conclusions
The chalcogen group of the periodic table provides no less than
three elements that are incorporatedintobiologicalmacromolecules:
oxygen, sulfur and selenium. As one mechanism of control in
selenium metabolism, higher eukaryotes have developed SCL
proteins that are specific for Sec. When analyzing a set of variants
of hSCL, a single D146K substitution was here found to be both
necessaryandsufficienttoobtainCDactivityandloseSecspecificity.
Thus we have defined a molecular determinant that conveys
selenium specificity to human SCL. Interestingly a single amino acid
residue, not directly participating in catalysis, was found to provide
this specificity. hSCL is thus a salient example of how more stringent
chemistry can be evolved in certain enzymes of a larger group while
keeping the same overall structure, cofactor and active site
architecture. We also found that the structural properties of the
active site dynamic segment of hSCL are well suited for control and
delivery of selenium. It seems reasonable that these elegant features
of the enzyme act together as a means to avoid release of toxic Se-
species in cells during turnover and synthesis of selenoproteins.
Materials and Methods
Cloning and protein expression
The hSCL cDNA clone was purchased from the Mammalian
Gene Collection (Genebank accession no. BC007891.2). The
sequence encoding residues 8–445 was amplified by PCR using
primers ‘‘forward TACTTCCAATCCATGGGGAGGGATGC-
GCCGG’’, and ‘‘reverse TATCCACCTTTACTGTCAGGCC-
TGGTCCTCCAGCTG’’) and inserted into pNIC-Bsa4 vector
(Genbank accession no. EF198106) by ligation independent
cloning. The construct included an N-terminal tag consisting of a
6-His sequence separated from the hSCL sequence by a TEV
protease cleavage site. For expression the pNIC-Bsa4 containing the
insert was transformed into the E. coli BL21(DE3) strain and stored at
280uC as a glycerol stock. Cells from the glycerol stock were used to
inoculate 20 ml of Terrific Broth (TB) supplemented with 8 g/l
glycerol and 100 mg/ml kanamycin and grown at 30uCo v e rn i g h t .
The 20 ml culture was used to inoculate 1.5 l TB media
supplemented with 8 g/l glycerol, 50 mg/ml kanamycin and 5 drops
of BREOX anti-foaming agent (Cognis Performance Chemicals UK
Ltd) in a 2 l glass flask. Cells were grown in a Large Scale Expression
System (LEX, Harbinger Biotechnology) at 37uCu n t i lt h eO D 600
Figure 2. Electron density for the dynamic segment. A and B) Stereo figure of an Fo-Fc difference electron density omit map of the segment
surrounding C388 for chains A and B, contoured at 2.5s (0.11 eA ˚-3).
doi:10.1371/journal.pone.0030581.g002
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whereupon expression of hSCL was induced by the addition of
0.5 mM IPTG and subsequently continued over night at 18uC. Cells
were harvested by centrifugation at 55006g for 10 min. at 4uCa n d
the pellet was resuspended in lysis buffer containing 50 mM Na-
phosphate pH 7.5, 500 mM NaCl, 10% glycerol, 10 mM imidazole,
0.5 mM TCEP, and Complete EDTA-free protease inhibitor (Roche
Biosciences). Resuspended cells were stored at 280uC.
Figure 3. Active site. A) Human SCL in pink showing the PLP binding site and E. coli NifS/CsdB (PDB: 1KMK) with the Cys-sulfoselenide intermediate
in blue showing the similar positioning of the C388-sulfur atom (hSCL) and that of C364 in E. coli NifS/CsdB. A second Sec substrate molecule, bound
to the PLP in the E. coli NifS/CsdB [21], is also shown. B) Electron density for the C388 persulfide in subunit A after a 2 h Cys soak of a P1 spacegroup
hSCL crystal. Fo-Fc difference electron density map of the C388 persulfide with the d-sulfur omitted contoured at 4s (0.23 eA ˚-3). C) Position of
mutated residues D146K, V256S and H389T in relation to C388 and the PLP cofactor.
doi:10.1371/journal.pone.0030581.g003
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The frozen cell suspension was thawed and 4 ml of 250 U/ml
benzonase (Novagen) was added per 50 ml of suspension. The
sample was sonicated on ice (Sonics VibraCell) at 80% amplitude,
4 sec on, 4 sec off for a total of 3 min followed by centrifugation at
49 0006g for 20 min. at 4uC. The soluble fraction was decanted
and filtered through a 0.45 mm filter.
Purification of the protein was performed as a two-step process
on an A ¨KTAxpress system (GE Helthcare). First step, metal
affinity chromatography using 1 ml HiTrap Chelating column
(GE Helthcare) and second step, gel filtration using, Superdex 200
gel filtration column (HiLoad 16/60; GE Healthcare). Prior to
purification, the HiTrap Chelating column was equilibrated with
buffer1 (50 mM Na-phosphate pH 7.5, 500 mM NaCl, 10%
glycerol, 10 mM imidazole, 0.5 mM TCEP) and the Superdex
200 was equilibrated with buffer2 (20 mM Hepes pH 7.5, 300 mM
NaCl, 10% glycerol, 0.5 mM TCEP. The filtered lysate was
loaded onto the Ni-charged HiTrap Chelating column and
washed with buffer1 followed by buffer1 supplemented with
imidazole to a final concentration of 25 mM. Bound protein was
eluted from the column with buffer1 containing 500 mM imidazole
and automatically loaded onto the gel filtration column, and
subsequently eluted using buffer2. The UV280 absorption chro-
matogram of the eluate showed a single major peak at a retention
volume of 74 ml. This peak consisted of hSCL as analyzed by
SDS-PAGE and the fractions from the peak were colored bright
yellow from the bound PLP cofactor. Fresh TCEP was added to
the pooled fractions to a final concentration of 2 mM and the
protein was then concentrated to 22.8 mg/ml (2.9 ml) using an
Amicon Ultra 15 (Millipore) centrifugal concentrator with a
30 kDa cut-off. The concentrated protein sample was finally
aliquoted and flash-frozen in liquid nitrogen for storage at 280uC.
Protein identity was confirmed by mass spectrometry.
His-tag removal
Prior to analysis or crystallization the His-tag was cleaved off by
adding TEVSH, a His-tagged TEV protease [40]. A total amount
of 30 mg SCL was mixed with TEVSH at a molar ratio of 30:1 in a
volume of 1.8 ml in buffer2 with 2 mM TCEP. Reaction was
performed at 4uC over night. Removal of the His-tag and the TEV
Figure 4. Alignment of representative sequences of bacterial SCL/CD enzymes (Synechocystis SufS, E. coli NifS, E. coli IscS and T.
maritima NifS) and Mammalian Sec-specific SCLs (Mouse, Rat and Human). Residue positions corresponding to D146, V256 and H389 (hSCL
numbering) are indicated with a yellow, green and purple background respectively.
doi:10.1371/journal.pone.0030581.g004
Figure 5. Activity of wild-type and variant proteins. A) Activity of
WT hSCL and variants containing the D146K substitution with Cys. WT
hSCL, solid black line and open circles; D146K/V256S/H389T, dotted
grey line and closed diamonds; D146K, dot-dash black line and stars;
D146K/V256S, dash black line and open squares; D146K/H389T, solid
black line and filled triangles. B) Activity of WT hSCL and the D146K/
H389T variant with Sec. WT, black line and open circles; D146K/H389T
variant, grey line and open squares.
doi:10.1371/journal.pone.0030581.g005
Figure 6. Conformations of the active site dynamic segment
(blue). A) Closed, B) Open. The sulfur atom of C388 is shown in yellow.
doi:10.1371/journal.pone.0030581.g006
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onto a 1 ml HisTrap crude column (GE Helthcare) equilibrated
with buffer1, whereby cleaved protein was eluted with buffer1
supplemented with 35 mM imidazole. Buffer was exchanged to
buffer2, 20 mM Hepes, 300 mM NaCl, 10% glycerol, pH 7.5,
2 mM TCEP. The hSCL protein was concentrated to 35.6 mg/
ml. Before assaying, the protein was treated with EDTA, which
was then removed by dialysis against the buffer2.
Construction of variants
Variant SCLY constructs were made by using the Stratagene
QuikChangeH Multi Site-Directed Mutagenesis Kit using primers;
D146K: 59- cctcggtggaacacaagtccatccggctgcc-39; V256S: 59- ggg-
cgtggacttccttacaatctcggggcacaagttttatg-39; H389T: 59- ggggccgc-
gtgcacctcggaccacgg-39, positions differing from wild-type are
indicated in bold. After sequence confirmation, the variant
constructs were transformed into E.coli BL21(DE3)R3 pRARE cells.
Crystallization, data collection and phasing
Initial crystallization conditions were identified from the JCSG+
crystal screen (QIAGEN). Crystals were grown from sitting drops
containing 0.1 ml of protein solution (17 mg/ml)+0.1 ml well
solution having 100 mM HEPES pH 6.7 and 10% PEG6000
that were left to equilibrate against the well solution. Crystals were
grown at 20uC and appeared after three days. Data was collected
at the ESRF, beam-line ID23-1 at l=1.071 A ˚ and 100 K. Data
was processed with XDS and XSCALE [41]. The space group was
P212121 with cell parameters a=59.2 A ˚ b=86.8 A ˚ c=189.6 A ˚
and one protein dimer in the asymmetric unit. The structure was
solved by Molecular Replacement using a monomer of the E. coli
cysteine desulfurase IscS (pdb entry: 1P3W) as the search model.
Refmac [42] was used for refinement and Coot [43] for model
building. TLS refinement with 4 TLS groups was used in Refmac.
The final model starts at Glu29 and ends at Gln444, the
penultimate residue in the sequence. Residues 120 to 132 in both
monomers are disordered and could not be detected in the
electron density. 92.3% of the residues are in the favored region,
7.3% in the allowed, 0.4% in the generously allowed and no
residues in the disallowed region of the Ramachandran plot
calculated using PROCHECK [44]. In addition, diffraction data
was also collected from crystals grown from sitting drops
containing 0.1 ml of protein solution (17 mg/ml) with 0.1 ml well
solution containing 50 mM HEPES pH 8.1, 200 mM Ammonium
Nitrate and 25% PEG3350 that were left to equilibrate against the
well solution. In this case, crystals appeared after seven days at
20uC. Crystals were incubated in well solution supplemented with
10 mM L-cysteine for 2 hours. Data was collected at the ESRF,
beam-line BM14 at l=0.9800 A ˚ and 100 K. Data was processed
with XDS and XSCALE [41]. The space group was P1 with cell
parameters a=66.6 A ˚, b=72.2 A ˚, c=89.4 A ˚, a=83.9u
b=68.4u, c=87.0u. The structure was solved by Molecular
Replacement using a monomer of the P212121 structure as the
search model. The asymmetric unit contained two protein dimers.
Refmac [42] was used for refinement and Coot [43] for model
building. The final model starts at Lys31 and ends at Gln444.
Residues 120 to 132 were disordered and invisible in the electron
density, which in this case was also the case for the active site loop
residues 391 to 394. 92.7% of the residues are in the favored
region, 7.3% in the allowed and no residues in the generously or
disallowed regions of the Ramachandran plot calculated using
PROCHECK [44]. Coordinates and structure factors have been
deposited in the PDB with accession numbers 3GZC and 3GZD.
SCL and CD activity assay
Spectrophotometric assays of SCL or CD activities were
performed as follows: A reaction solution containing 10 mM Cys
or 5 mM seleno-L-cystine (Fluka), 0.2 mM PLP, 50 mM DTT,
0.04 mg/ml BSA, 120 mM Tris-HCl pH 8.5, was deoxygenated
by bubbling nitrogen through it before the addition of enzyme
(1 ml), resulting in 35 mg/ml (0.73 mM) enzyme in a final volume of
100 ml. For control reactions the enzyme was first denatured by
heating to 80uC for 2 min. Reactions were incubated under
nitrogen at 37uC for durations as stated in the text, before
termination of the reaction by heating to 80uC for 3 min. All
assays were repeated in triplicate. The product alanine was
detected in an alanine dehydrogenase reporter assay as follows: A
reaction mixture was made containing 100 mM sodium bicar-
bonate/carbonate pH 10.0, 0.6 mM NAD+, 0.1 U L-alanine
Figure 7. Potential mechanism of selenide product delivery directly to selenophosphate synthetase by the C388-containing flexible
active site segment.
doi:10.1371/journal.pone.0030581.g007
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(see above) in a final volume of 50 ml. In the case of reactions
performed using Sec as substrate, 10 ml of a 100 mM lead acetate
suspension in water was first added to the SCL reaction to allow
removal of selenium by centrifugation before 5 ml of the
supernatant was added to the alanine dehydrogenase reaction.
After incubation at 25uC for 20 min the absorption spectrum from
220 to 750 nm was measured. NADH formation was determined
from the absorbance at 341 nm. Absorption values for denatured
enzyme control assays were subtracted from values obtained using
the native enzymes and alanine concentrations were estimated
using a standard curve.
Acknowledgments
The assistance of staff at beamlines ID23-1 and BM14 at the ESRF in
Grenoble is gratefully acknowledged.
Author Contributions
Conceived and designed the experiments: RC ESJA LHS PB M. Ho ¨gbom.
Performed the experiments: RC SvdB NM KO TK M. Hammarstro ¨mAF
LHS M. Ho ¨gbom. Analyzed the data: RC A-LJ TK NM ESJA HS PB
M. Ho ¨gbom. Wrote the paper: RC TK SvdB ESJA M. Ho ¨gbom.
References
1. Allmang C, Wurth L, Krol A (2009) The selenium to selenoprotein pathway in
eukaryotes: more molecular partners than anticipated. Biochim Biophys Acta
1790: 1415–1423.
2. Yoshizawa S, Bock A (2009) The many levels of control on bacterial
selenoprotein synthesis. Biochim Biophys Acta 1790: 1404–1414.
3. Kryukov GV, Castellano S, Novoselov SV, Lobanov AV, Zehtab O, et al. (2003)
Characterization of mammalian selenoproteomes. Science 300: 1439–1443.
4. Letavayova L, Vlckova V, Brozmanova J (2006) Selenium: from cancer
prevention to DNA damage. Toxicology 227: 1–14.
5. Schomburg L, Schweizer U, Kohrle J (2004) Selenium and selenoproteins in
mammals: extraordinary, essential, enigmatic. Cell Mol Life Sci 61: 1988–1995.
6. Angstwurm MW, Gaertner R (2006) Practicalities of selenium supplementation
in critically ill patients. Curr Opin Clin Nutr Metab Care 9: 233–238.
7. Carlson BA, Xu XM, Kryukov GV, Rao M, Berry MJ, et al. (2004)
Identification and characterization of phosphoseryl-tRNA[Ser]Sec kinase. Proc
Natl Acad Sci U S A 101: 12848–12853.
8. Xu XM, Carlson BA, Mix H, Zhang Y, Saira K, et al. (2007) Biosynthesis of
selenocysteine on its tRNA in eukaryotes. PLoS Biol 5: e4.
9. Yuan J, Palioura S, Salazar JC, Su D, O’Donoghue P, et al. (2006) RNA-
dependent conversion of phosphoserine forms selenocysteine in eukaryotes and
archaea. Proc Natl Acad Sci U S A 103: 18923–18927.
10. Palioura S, Sherrer RL, Steitz TA, Soll D, Simonovic M (2009) The human
SepSecS-tRNASec complex reveals the mechanism of selenocysteine formation.
Science 325: 321–325.
11. Kumar S, Bjornstedt M, Holmgren A (1992) Selenite is a substrate for calf
thymus thioredoxin reductase and thioredoxin and elicits a large non-
stoichiometric oxidation of NADPH in the presence of oxygen. Eur J Biochem
207: 435–439.
12. Gromer S, Gross JH (2002) Methylseleninate is a substrate rather than an
inhibitor of mammalian thioredoxin reductase. Implications for the antitumor
effects of selenium. J Biol Chem 277: 9701–9706.
13. Esaki N, Nakamura T, Tanaka H, Soda K (1982) Selenocysteine lyase, a novel
enzyme that specifically acts on selenocysteine. Mammalian distribution and
purification and properties of pig liver enzyme. J Biol Chem 257: 4386–4391.
14. Esaki N, Karai N, Nakamura T, Tanaka H, Soda K (1985) Mechanism of
reactions catalyzed by selenocysteine beta-lyase. Arch Biochem Biophys 238:
418–423.
15. Suzuki KT, Kurasaki K, Suzuki N (2007) Selenocysteine beta-lyase and
methylselenol demethylase in the metabolism of Se-methylated selenocom-
pounds into selenide. Biochim Biophys Acta 1770: 1053–1061.
16. Mihara H, Kurihara T, Watanabe T, Yoshimura T, Esaki N (2000) cDNA
cloning, purification, and characterization of mouse liver selenocysteine lyase.
Candidate for selenium delivery protein in selenoprotein synthesis. J Biol Chem
275: 6195–6200.
17. Burk RF, Hill KE (2009) Selenoprotein P-expression, functions, and roles in
mammals. Biochim Biophys Acta 1790: 1441–1447.
18. Daher R, Van Lente F (1992) Characterization of selenocysteine lyase in human
tissues and its relationship to tissue selenium concentrations. J Trace Elem
Electrolytes Health Dis 6: 189–194.
19. Lacourciere GM, Stadtman TC (1998) The NIFS protein can function as a
selenide delivery protein in the biosynthesis of selenophosphate. J Biol Chem
273: 30921–30926.
20. Mihara H, Kurihara T, Yoshimura T, Esaki N (2000) Kinetic and mutational
studies of three NifS homologs from Escherichia coli: mechanistic difference
between L-cysteine desulfurase and L-selenocysteine lyase reactions. J Biochem
(Tokyo) 127: 559–567.
21. Lima CD (2002) Analysis of the E. coli NifS CsdB protein at 2.0 A reveals the
structural basis for perselenide and persulfide intermediate formation. J Mol Biol
315: 1199–1208.
22. Mihara H, Kurihara T, Yoshimura T, Soda K, Esaki N (1997) Cysteine sulfinate
desulfinase, a NIFS-like protein of Escherichia coli with selenocysteine lyase and
cysteine desulfurase activities. Gene cloning, purification, and characterization of
a novel pyridoxal enzyme. J Biol Chem 272: 22417–22424.
23. Mueller EG (2006) Trafficking in persulfides: delivering sulfur in biosynthetic
pathways. Nat Chem Biol 2: 185–194.
24. Outten FW, Wood MJ, Munoz FM, Storz G (2003) The SufE protein and the
SufBCD complex enhance SufS cysteine desulfurase activity as part of a sulfur
transfer pathway for Fe-S cluster assembly in Escherichia coli. J Biol Chem 278:
45713–45719.
25. Shi R, Proteau A, Villarroya M, Moukadiri I, Zhang L, et al. (2010) Structural
basis for Fe-S cluster assembly and tRNA thiolation mediated by IscS protein-
protein interactions. PLoS Biol 8: e1000354.
26. Lacourciere GM (2002) Selenium is mobilized in vivo from free selenocysteine
and is incorporated specifically into formate dehydrogenase H and tRNA
nucleosides. J Bacteriol 184: 1940–1946.
27. Lacourciere GM, Mihara H, Kurihara T, Esaki N, Stadtman TC (2000)
Escherichia coli NifS-like proteins provide selenium in the pathway for the
biosynthesis of selenophosphate. J Biol Chem 275: 23769–23773.
28. Lacourciere GM, Stadtman TC (1999) Catalytic properties of selenophosphate
synthetases: comparison of the selenocysteine-containing enzyme from Hae-
mophilus influenzae with the corresponding cysteine-containing enzyme from
Escherichia coli. Proc Natl Acad Sci U S A 96: 44–48.
29. Mihara H, Kato S, Lacourciere GM, Stadtman TC, Kennedy RA, et al. (2002)
The iscS gene is essential for the biosynthesis of 2-selenouridine in tRNA and the
selenocysteine-containing formate dehydrogenase H. Proc Natl Acad Sci U S A
99: 6679–6683.
30. Tamura T, Yamamoto S, Takahata M, Sakaguchi H, Tanaka H, et al. (2004)
Selenophosphate synthetase genes from lung adenocarcinoma cells: Sps1 for
recycling L-selenocysteine and Sps2 for selenite assimilation. Proc Natl Acad
Sci U S A 101: 16162–16167.
31. Ogasawara Y, Lacourciere GM, Ishii K, Stadtman TC (2005) Characterization
of potential selenium-binding proteins in the selenophosphate synthetase system.
Proc Natl Acad Sci U S A 102: 1012–1016.
32. Omi R, Kurokawa S, Mihara H, Hayashi H, Goto M, et al. (2010) Reaction
mechanism and molecular basis for selenium/sulfur discrimination of seleno-
cysteine lyase. J Biol Chem 285: 12133–12139.
33. Schneider G, Kack H, Lindqvist Y (2000) The manifold of vitamin B6
dependent enzymes. Structure 8: R1–6.
34. Johansson A-L, Collins R, Arne ´r ESJ, Brzezinski P, Ho ¨gbom M (2012)
Biochemical discrimination between selenium and sulfur 2: Mechanistic
investigation of the selenium specificity of human selenocysteine lyase. PLoS
ONE;In press.
35. Liu SY, Stadtman TC (1997) Selenophosphate synthetase: enzyme labeling
studies with [gamma-
32P]ATP, [beta-
32P]ATP, [8-
14C]ATP, and [
75Se]selenide.
Arch Biochem Biophys 341: 353–359.
36. Itoh Y, Sekine S, Matsumoto E, Akasaka R, Takemoto C, et al. (2009) Structure
of selenophosphate synthetase essential for selenium incorporation into proteins
and RNAs. J Mol Biol 385: 1456–1469.
37. Tobe R, Mihara H, Kurihara T, Esaki N (2009) Identification of proteins
interacting with selenocysteine lyase. Biosci Biotechnol Biochem 73: 1230–1232.
38. Xu XM, Carlson BA, Irons R, Mix H, Zhong N, et al. (2007) Selenophosphate
synthetase 2 is essential for selenoprotein biosynthesis. Biochem J 404: 115–20.
39. Lobanov AV, Hatfield DL, Gladyshev VN (2008) Selenoproteinless animals:
selenophosphate synthetase SPS1 functions in a pathway unrelated to
selenocysteine biosynthesis. Protein Sci 17: 176–82.
40. van den Berg S, Lofdahl PA, Hard T, Berglund H (2006) Improved solubility of
TEV protease by directed evolution. J Biotechnol 121: 291–298.
41. Kabsch W (1993) Automatic Processing of Rotation Diffraction Data from
Crystals of Initially Unknown Symmetry and Cell Constants. J Appl Cryst 26:
795–800.
42. Murshudov GN, Vagin AA, Dodson EJ (1997) Refinement of macromolecular
structures by the maximum-likelihood method. Acta Cryst D 53: 240–255.
43. Emsley P, Cowtan K (2004) Coot: model-building tools for molecular graphics.
Acta Crystallogr D Biol Crystallogr 60: 2126–2132.
44. Laskowski RA, Macarthur MW, Moss DS, Thornton JM (1993) Procheck - A
Program to Check the Stereochemical Quality of Protein Structures. J Appl
Cryst 26: 283–291.
Selenium Specificity of Human Selenocysteine Lyase
PLoS ONE | www.plosone.org 10 January 2012 | Volume 7 | Issue 1 | e30581